| scientific journal | Q5633421 |
| P8375 | Crossref journal ID | 53726 |
| P1058 | ERA Journal ID | 41701 |
| P8903 | HAL journal ID | 39097 |
| P236 | ISSN | 1479-6708 |
| 1748-6971 | ||
| P7363 | ISSN-L | 1479-6708 |
| P1277 | JUFO ID | 81372 |
| P1055 | NLM Unique ID | 101278119 |
| P856 | official website | http://www.futuremedicine.com/loi/fnl |
| P10283 | OpenAlex ID | S99603113 |
| P3181 | OpenCitations bibliographic resource ID | 369285 |
| P7662 | Scilit journal ID | 2278023 |
| P1156 | Scopus source ID | 5900153302 |
| P275 | copyright license | Creative Commons Attribution-NonCommercial-NoDerivatives | Q6937225 |
| P495 | country of origin | United Kingdom | Q145 |
| P8875 | indexed in bibliographic review | Scopus | Q371467 |
| Emerging Sources Citation Index | Q22908122 | ||
| P407 | language of work or name | English | Q1860 |
| P123 | publisher | Future Medicine | Q28401954 |
| P1476 | title | Future Neurology |
| Q58456351 | 10th European Meeting on Glial Cells in Health and Disease |
| Q36379761 | A Critical Kinase Cascade in Neurological Disorders: PI 3-K, Akt, and mTOR. |
| Q35588323 | A new look at glutamate and ischemia: NMDA agonist improves long-term functional outcome in a rat model of stroke |
| Q38649558 | A report of nontraumatic cortical subarachnoid hemorrhage and subsequent management |
| Q36737627 | ADVANCES IN THE CELL-BASED TREATMENT OF NEONATAL HYPOXIC-ISCHEMIC BRAIN INJURY |
| Q62036146 | Activity of the novel T137A SOD1 mutation in amyotrophic lateral sclerosis patients |
| Q60689118 | Acute demyelination in children: predicting pediatric multiple sclerosis manifestation |
| Q37029454 | Advances in the treatment of visual hallucinations in neurodegenerative diseases. |
| Q129593780 | Advancing personalized treatment of Alzheimer's disease: a call for the N-of-1 trial design |
| Q127099476 | Aging and eye tracking: in the quest for objective biomarkers |
| Q36518304 | Aging of the NMDA receptor: from a mouse's point of view |
| Q39495779 | Alleviating brain stress: what alternative animal models have revealed about therapeutic targets for hypoxia and anoxia |
| Q60681504 | Alterations in pain responsiveness and serum biomarkers in juvenile myoclonic epilepsy: an age- and gender-matched controlled pilot study |
| Q39598179 | Alzheimer's disease and epilepsy: insight from animal models |
| Q57777631 | Alzheimer’s disease therapy: focus on synapses |
| Q39420600 | Amyloid precursor protein and tau transgenic models of Alzheimer‘s disease: insights from the past and directions for the future |
| Q58005714 | Amyloid-related imaging abnormalities associated with immunotherapy in Alzheimer’s disease patients |
| Q30910766 | Anatomical, functional and molecular biomarker applications of magnetic resonance neuroimaging |
| Q34700931 | Animal models of stroke: translational potential at present and in 2050 |
| Q34019994 | Antidepressant-coincident mania in children and adolescents treated with selective serotonin reuptake inhibitors |
| Q57911815 | Application of fMRI to the study of multiple sclerosis: an update |
| Q60681500 | Aquaporins in peripheral nociception |
| Q33574289 | Association of epilepsy and comorbid conditions |
| Q61771783 | Astrocyte toxicity in motor neuron disease: progress and future hopes |
| Q36819902 | Astroglia in neurological diseases |
| Q36893822 | Autophagy in neuroprotection and neurodegeneration: A question of balance. |
| Q38420841 | Axonal tract tracing for delineating interacting brain regions: implications for Alzheimer's disease-associated memory |
| Q128564469 | Back to the future: Stoic wisdom and psychotherapy for neuropsychiatric conditions |
| Q60681497 | Botulinum neurotoxin type A combined with functional electrical stimulation for upper-limb poststroke spasticity with pain |
| Q57194161 | Bulletin Board: Highlighting the latest news and research in neurology |
| Q36822034 | CNS autoimmune disease after Streptococcus pyogenes infections: animal models, cellular mechanisms and genetic factors |
| Q59902370 | Cell specificity of altered cation–chloride cotransporter expression and GABAergic innervation in the epileptic cerebral cortex |
| Q38092677 | Cellular mechanisms for altered learning in aging. |
| Q57341492 | Cerebrotendinous xanthomatosis: a critical update |
| Q59600499 | Challenging the classical distinction between long-term and short-term memory: reconsidering the role of the hippocampus |
| Q126356913 | Chronic stress, physiological adaptation and developmental programming of the neuroendocrine stress system |
| Q38021993 | Clearance of amyloid-β peptides by microglia and macrophages: the issue of what, when and where |
| Q127820838 | Clinical and demographic features in Iranian multiple sclerosis patients: a systematic review and meta-analysis |
| Q37436473 | Clinical and molecular aspects of varicella zoster virus infection |
| Q60629541 | Cognitive decline and cerebrospinal fluid biomarkers: a close relationship |
| Q57544741 | Cognitive dysfunction in patients with epilepsy: focus on clinical variables |
| Q47552092 | Comorbid autism spectrum disorder and anxiety disorders: a brief review |
| Q59851996 | Corpus callosum in cognitive and sensory processing: insights into autism |
| Q57422415 | Corrigendum |
| Q38603960 | Corticostriatal circuit dysfunction in Huntington's disease: intersection of glutamate, dopamine and calcium |
| Q37301354 | Corticotropin-Releasing Hormone (CRH) Programs the Fetal and Maternal Brain |
| Q58035363 | Could ignoring higher blood sugar levels in the normal range in nondiabetics compromise cerebral health? |
| Q127821885 | Could novel diagnostic technology Cognetivity accelerate dementia research? An interview with Dr Sina Habibi |
| Q57521580 | Current developments in MRI for assessing rodent models of multiple sclerosis |
| Q55502131 | Deep-brain stimulation |
| Q127109134 | Dendritic polyglycerols are modulators of microglia-astrocyte crosstalk |
| Q33670661 | Development of histone deacetylase inhibitors as therapeutics for neurological disease |
| Q30482920 | Developmental hearing loss disrupts synaptic inhibition: implications for auditory processing |
| Q63677341 | Diagnosis and management of pediatric peripheral neuropathies in resource-poor settings |
| Q30747071 | Diffusion tensor imaging and related techniques in tuberous sclerosis complex: review and future directions. |
| Q57708984 | Discovering the connection between familial and sporadic amyotrophic lateral sclerosis: pathology trumps genetics |
| Q61570731 | Dopamine system genes and ADHD: a review of the evidence |
| Q33654916 | Dopamine transporter trafficking: rapid response on demand |
| Q37386063 | Early Detection of Huntington Disease |
| Q61853468 | Early markers for cerebral palsy: insights from the assessment of general movements |
| Q61439741 | Elastic fibers and amyloid deposition in vascular tissue |
| Q127812674 | Electroencephalogram and somatosensory evoked potential evaluation for good and poor neurological prognosis after cardiac arrest: a prospective multicenter cohort trial (ProNeCA) |
| Q61982547 | Emerging genomic biomarkers in migraine |
| Q58621536 | Erbin in cortical inhibition |
| Q37591222 | Essential function, sophisticated regulation and pathological impact of the selective RNA-binding protein QKI in CNS myelin development |
| Q34135724 | Estimating and disclosing the risk of developing Alzheimer‘s disease: challenges, controversies and future directions |
| Q61649746 | European stroke strategies: current status and problems to be solved |
| Q33649463 | Evidence for RNA-mediated toxicity in the fragile X-associated tremor/ataxia syndrome |
| Q39669368 | Evidence from the R6/2 Mouse Model of Huntington's Disease for Using Abnormal Brain Metabolism as a Biomarker for Evaluating Therapeutic Approaches for Treatment |
| Q57313010 | Evidence-to-practice gaps in post-stroke management: a focus on care in a stroke unit and anticoagulation to prevent death, disability and recurrent stroke |
| Q57200142 | Exome and genome sequencing of neonates with neurodevelopmental disorders |
| Q37324227 | Experience--a double edged sword for restorative neural plasticity after brain damage |
| Q34822324 | Facial neuropathy with imaging enhancement of the facial nerve: a case report |
| Q39734933 | Fetal neurosurgery: current state of the art. |
| Q60042420 | Focusing on atypical symptoms for improved diagnosis of early-onset Alzheimer’s disease |
| Q89848611 | Fragile X- associated Neuropsychiatric Disorders: A Case Report |
| Q59557497 | From pneumomyelography to cord tractography: historical perspectives on spinal imaging |
| Q30552041 | From singing to speaking: facilitating recovery from nonfluent aphasia |
| Q113222787 | Funding for spinal muscular atrophy research must continue |
| Q58619261 | Future advances in the treatment of acute ischemic stroke |
| Q127825151 | Gabapentin completely neutralized the acute morphine activation in the rat hypothalamus: a c-Fos study |
| Q58297392 | Gangliogliomas: recent advances in classification and treatment |
| Q60689094 | Gene pathway analyses for multiple sclerosis point to cellular adhesion molecules as susceptibility factors |
| Q57677438 | Gene therapy for Rett syndrome: prospects and challenges |
| Q39069604 | Genetic loci associated with Alzheimer's disease |
| Q60689113 | Genetic modifiers of Huntington’s disease: beyond CAG |
| Q57741569 | Grid infrastructures for computational neuroscience: the neuGRID example |
| Q37012791 | Growth factor regulation of remyelination: behind the growing interest in endogenous cell repair of the CNS. |
| Q59610964 | Harnessing experience-dependent plasticity for CNS repair and regeneration |
| Q126316489 | How does editing the genome improve targeting DNA and RNA for cerebellar ataxias? |
| Q59852029 | How important is the corpus callosum in resting-state networks? |
| Q128526499 | Human cerebral organoids and neural 3D tissues in basic research, and their application to study neurological diseases |
| Q35064053 | Human-derived natural antibodies: biomarkers and potential therapeutics |
| Q127314500 | Imaging markers of disease progression in multiple system atrophy |
| Q37414788 | In vivo astrocytic Ca(2+) signaling in health and brain disorders |
| Q39101531 | In vivo characterization of brain iron with magnetic field correlation imaging |
| Q37414772 | Inflammation and human cerebral aneurysms: current and future treatment prospects. |
| Q36911060 | Inherited disorders of GABA metabolism |
| Q48056810 | Inositol depletion, GSK3 inhibition and bipolar disorder |
| Q37784147 | Insights into neurogenesis and aging: potential therapy for degenerative disease? |
| Q33964940 | Insights into synaptic function from mouse models of human cognitive disorders |
| Q34193229 | Inter-relationships among behavioral markers, genes, brain and treatment in dyslexia and dysgraphia |
| Q126360158 | Interferon beta-1a induces expression of brain-derived neurotrophic factor in human T lymphocytes in vitro and not in vivo |
| Q39909606 | Is abnormal axonal transport a cause, a contributing factor or a consequence of the neuronal pathology in Alzheimer's disease? |
| Q129759881 | Is cognitive training able to improve brain functioning with age? |
| Q59134386 | Is xenon a future neuroprotectant? |
| Q37259848 | It's all in the family: multiple Toll-like receptors offer promise as novel therapeutic targets for stroke neuroprotection |
| Q56749706 | Japanese encephalitis: perspectives and new developments |
| Q60732956 | L-kynurenine: metabolism and mechanism of neuroprotection |
| Q35655078 | Lasting impacts of prenatal cannabis exposure and the role of endogenous cannabinoids in the developing brain. |
| Q59416769 | Late-life depression as a risk factor for dementia |
| Q60716926 | Long-term administration of fluoxetine to improve motor recovery after stroke |
| Q29040677 | Looking at Alzheimer‘s disease from a different angle |
| Q57487833 | Low-dose doxepin (3 and 6 mg) for the treatment of insomnia |
| Q129997953 | Low-sodium oxybate improved symptoms in adults with narcolepsy with cataplexy: a plain language summary of publication |
| Q36607929 | Malignant synaptic growth and Alzheimer's disease |
| Q91664938 | Management of epilepsy during pregnancy: evidence-based strategies |
| Q55897261 | Mania: a rational neurobiology |
| Q61651622 | Mechanisms of T-cell migration across the BBB |
| Q60627136 | Metacognition, self-reflection and recovery in schizophrenia |
| Q60955707 | Microarray analysis of gene expression profiles in human neuroblastoma cells exposed to Aβ–Zn and Aβ–Cu complexes |
| Q37733265 | Microglia in ischemic brain injury |
| Q37723883 | Migraine and obesity: moving beyond BMI. |
| Q37897966 | Modeling neurological diseases using patient-derived induced pluripotent stem cells |
| Q37523317 | Molecular contributions to neurovascular unit dysfunctions after brain injuries: lessons for target-specific drug development |
| Q57982414 | Molecular determinants of Alzheimer’s disease Aβ peptide neurotoxicity |
| Q128536145 | Molecular genetics of medulloblastoma in children: diagnostic, therapeutic and prognostic implications |
| Q36330352 | Molecular neuropathogenesis of Alzheimer's disease: an interaction model stressing the central role of oxidative stress |
| Q92510092 | Motor neuron biology and disease: A current perspective on infantile-onset spinal muscular atrophy |
| Q58380973 | Natural disasters and the neurodevelopmental response to trauma in childhood: a brief overview and call to action |
| Q58205761 | Neonatal ischemic stroke: a hypoxic–ischemic injury to the developing brain |
| Q30398021 | Neural pathways for language in autism: the potential for music-based treatments |
| Q58621554 | Neuregulin-1 signaling in schizophrenia |
| Q33915824 | Neurobiology of dysregulated motivational systems in drug addiction |
| Q38197609 | Neurodegeneration in spinal muscular atrophy: from disease phenotype and animal models to therapeutic strategies and beyond |
| Q57341313 | Neurodegenerative processes in Alzheimer’s disease: an overview of pathogenesis with strategic biomarker potential |
| Q31159689 | Neuroimaging chronic pain: what have we learned and where are we going? |
| Q129760261 | Neuroinflammation and neurotoxicity contribute to neuroprogression in neurological and psychiatric disorders |
| Q127371271 | Neurological implications of nonfatal strangulation and intimate partner violence |
| Q37526739 | Neuronal adhesion and synapse organization in recovery after brain injury |
| Q62404386 | Neuronal ceroid lipofuscinoses: many players, and more to come |
| Q128342477 | Neuroprotection of multifunctional phytochemicals as novel therapeutic strategy for neurodegenerative disorders: antiapoptotic and antiamyloidogenic activities by modulation of cellular signal pathways |
| Q57564070 | Neuroprotection: where to now? |
| Q64899737 | New directions in therapeutics for Huntington disease. |
| Q57341506 | Nonestrogen-based hormonal therapies for Alzheimer’s disease |
| Q39900125 | Novel approaches to imaging epilepsy by MRI. |
| Q38801607 | Novel susceptibility loci for Alzheimer's disease |
| Q114252488 | Once-nightly sodium oxybate (FT218) improved symptoms in people with narcolepsy: a plain language summary of publication |
| Q36517220 | Opening Pandora's jar: a primer on the putative roles of CRMP2 in a panoply of neurodegenerative, sensory and motor neuron, and central disorders. |
| Q55140067 | Optimizing mouse models of neurodegenerative disorders: are therapeutics in sight? |
| Q60705078 | Our rapidly changing understanding of acute and chronic disorders of consciousness: challenges for neurologists |
| Q57243906 | PINK1: one protein, multiple neuroprotective functions |
| Q38606300 | Parkinson's Disease: What role do pedunculopontine nucleus cholinergic neurons play? |
| Q60657713 | Path to understanding the pathophysiology of Fragile X syndrome |
| Q37445764 | Pathogenesis of autism: a patchwork of genetic causes |
| Q129760315 | Pathological human astroglia in Alzheimer's disease: opening new horizons with stem cell technology |
| Q127823714 | Pathophysiology of migraine: an increasingly complex narrative to 2020 |
| Q36714458 | Persistent region-dependent neuroinflammation, NMDA receptor loss and atrophy in an animal model of penetrating brain injury |
| Q127108563 | Photic sneeze reflex: another variant of the trigeminocardiac reflex? |
| Q59505828 | Post-polio syndrome: clinical manifestations and cerebrospinal fluid markers |
| Q33588556 | Predicting dementia: role of dementia risk indices |
| Q56449415 | Prion protein in Alzheimer’s disease |
| Q60932286 | Progressive supranuclear palsy and corticobasal degeneration: similarities and differences |
| Q39389361 | Promoting neurological recovery of function via metaplasticity |
| Q37286540 | REST and the RESTless: in stem cells and beyond |
| Q62588559 | Radiation effects on neurogenic regions in the mammalian forebrain |
| Q37383972 | Recent Progress in Rett Syndrome and MeCP2 Dysfunction: Assessment of Potential Treatment Options |
| Q57244624 | Recent progress in the pharmacotherapy of bipolar disorder |
| Q58312104 | Recent progress of the Golgi technique and electron microscopy to examine dendritic pathology in Alzheimer’s disease |
| Q37845653 | Recent trends in rehabilitation interventions for visual neglect and anosognosia for hemiplegia following right hemisphere stroke |
| Q37259863 | Receptor for advanced glycation end products: its role in Alzheimer's disease and other neurological diseases |
| Q39114387 | Regional variability in Alzheimer's disease biomarkers. |
| Q61631186 | Regulation of corticolimbic reactivity via the 5-HT1A autoreceptor in the pathophysiology and treatment of depression |
| Q127824448 | Resting functional connectivity and mild cognitive impairment in Parkinson’s disease. An electroencephalogram study |
| Q57828783 | Risk factors for suicide in epilepsy patients |
| Q129593804 | Role of FABP3 as biomarker in Alzheimer's disease and synucleinopathies |
| Q58842294 | Role of amyloid-β–metal interactions in Alzheimer’s disease |
| Q63341546 | Role of cdk5 on ATM phosphorylation in neuronal death induced by DNA damage |
| Q60054719 | Role of central neurophysiological systems in placebo analgesia and their relationships with cognitive processes mediating placebo responding |
| Q127099315 | Seizures in cancer patients: a vast spectrum of etiologies |
| Q33685081 | Sex-specific responses to stroke |
| Q60147703 | Shunting for idiopathic normal-pressure hydrocephalus: can we predict response? |
| Q28391163 | Soluble Epoxide Hydrolase Inhibition: Targeting Multiple Mechanisms of Ischemic Brain Injury with a Single Agent |
| Q60681501 | Space headaches |
| Q56971276 | Spreading depolarization, a pathophysiological mechanism of stroke and migraine aura |
| Q113222794 | Stem cells and neurologic diseases: hope or hype? |
| Q36079327 | Stroke therapy: the potential of amniotic fluid-derived stem cells |
| Q59557703 | Subcortical gray matter structures: a future biomarker for amyotrophic lateral sclerosis? |
| Q59876019 | TGF-β signaling in Duchenne muscular dystrophy |
| Q60148895 | TRPV1: hot new channels in the brain |
| Q60681507 | Targeting glia in human pain: challenges and opportunities |
| Q127338613 | Teaching an old drug new tricks: repositioning strategies for spinal muscular atrophy |
| Q40097895 | The Implications of the Cancer Stem Cell Hypothesis for Neuro-Oncology and Neurology |
| Q57655240 | The OPTIMISE data project: toward improving multiple sclerosis treatment |
| Q129584020 | The burden of clinical neurophysiology for the neurological prognosis of coma |
| Q106369561 | The burden of oncology promises not kept in glioblastoma |
| Q30474232 | The clinical implications of mouse models of enhanced anxiety. |
| Q36799924 | The expanding genomic landscape of autism: discovering the 'forest' beyond the 'trees' |
| Q36697907 | The future of stem cell therapy for stroke rehabilitation |
| Q39913744 | The genetics of progressive hearing loss: a link between hearing impairment and dysfunction of mechanosensory hair cells |
| Q35222750 | The hippocampo-prefrontal pathway: a possible therapeutic target for negative and cognitive symptoms of schizophrenia |
| Q90039950 | The mTOR pathway in treatment of epilepsy: a clinical update |
| Q127253957 | The prevalence of delirium in patients in Iran: a systematic review and meta-analysis |
| Q127779567 | The rise and rise of cerebral small vessel disease: implications for vascular cognitive impairment and dementia |
| Q106369568 | The role of gender in glioblastoma: does it matter? |
| Q36474496 | The role of intracellular trafficking and the VPS10d receptors in Alzheimer's disease |
| Q59118273 | The role of microglia in neurogenesis: exercise and aging as cofactors |
| Q39349722 | The role of neuregulin-1 in the response to nerve injury |
| Q129801701 | The use of erenumab for migraine prevention: an interview with Andreas Gantenbein |
| Q33610240 | Therapeutic potential of statins in multiple sclerosis: immune modulation, neuroprotection and neurorepair |
| Q37327912 | Therapy development for neuromuscular diseases: translating hope into promise |
| Q57518128 | Therapy for dyskinesias in Parkinson’s disease patients |
| Q60681509 | Toward mechanism-based treatment of migraine: spotlight on CGRP |
| Q33863331 | Towards an Understanding of Neuropsychiatric Manifestations in Fragile X Premutation Carriers |
| Q37352964 | Transglutaminase activation in neurodegenerative diseases. |
| Q39129263 | Translating cerebellar Purkinje neuron physiology to progress in dominantly inherited ataxia |
| Q58154103 | Transthyretin in peripheral nerve regeneration |
| Q56806742 | Treatment-resistant depression: experience of the first repetitive transcranial magnetic stimulation clinic in the UK |
| Q57199920 | Understanding barrier mechanisms in the developing brain to aid therapy for the dysfunctional brain |
| Q37274157 | Understanding the neurobiology of CD200 and the CD200 receptor: a therapeutic target for controlling inflammation in human brains? |
| Q60681502 | Unfolding the hidden potential of venomics for chronic pain |
| Q59544577 | Unlocking the secrets of LRRK2 function with selective kinase inhibitors |
| Q39285976 | Unlocking truths of γ-secretase in Alzheimer's disease: what is the translational potential? |
| Q57814471 | Update on leukodystrophies |
| Q37395783 | Update on the functional biology of Lrrk2. |
| Q60055007 | Utility of biomarkers to improve the diagnosis and treatment of schizophrenia |
| Q126302686 | Welcome to the 15th volume of Future Neurology |
| Q128594229 | What are the challenges in migraine research? An interview with Parisa Gazerani |
| Q34701742 | What can post-mortem studies tell us about the pathoetiology of suicide? |
| Q47706142 | What goes up must come down: homeostatic synaptic plasticity strategies in neurological disease |
| Q30850844 | What have novel imaging techniques revealed about metabolism in the aging brain? |
| Q126358312 | What is the role of post acute EEG in prediction of late neurological outcome in severe disorders of consciousness? |
| Q117000865 | When a disease gene is not really a disease gene |
| Q56796063 | mGluR5: a potential target for the treatment of Huntington's disease |
| Q39429483 | mTOR as a potential treatment target for epilepsy |
| Q35932488 | α-synuclein, LRRK2 and their interplay in Parkinson's disease. |
| Q60681503 | ‘Omics’: an emerging field in pain research and management |
Search more.